References
- Shi Y, Xu Y, Shen H, Jin J, Tong H, Xie W. Advances in biology, diagnosis and treatment of DLBCL. Ann Hematol. 2024; 103:3315–34.
- Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018; 50:74–87.
- Dabrowska-Iwanicka A, Nowakowski GS. DLBCL: who is high risk and how should treatment be optimized? Blood. 2024; 144:2573–82.
- Hertzberg M. R-CHOP in DLBCL: priming for success. Blood. 2022; 139:1121–2.
- Issa DE, Dinmohamed AG, Wondergem MJ, Blommestein HM, Huijgens PC, Lugtenburg PJ, et al. A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in the Netherlands. Leuk Lymphoma. 2021; 62:549–59.
- Qualls D, Armand P, Salles G. The current landscape of frontline large B-cell lymphoma trials. Blood. 2025; 145:176–89.
- Zheng W, Chen Z, Zhu S, Cheng L, Hu Y, Yang Y, et al. Incidence and risk factors for febrile neutropenia of patients with diffuse large B-cell lymphoma receiving R-CHOP-21 in China. Support Care Cancer. 2023; 32:43. doi: 10.1007/s00520-023-08250-z
- Nakaphan P, Uaprasert N. Effects of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis for chemotherapy-induced febrile neutropenia in diffuse large B-cell lymphoma patients receiving the R-CHOP-21 regimen. Asian Biomed (Res Rev News). 2025; 19:165–73.
- Go SI, Jeong EJ, Lee WJ, Park S, Park MJ, Lee GW. Sarcopenia attenuates the efficacy of PEGylated granulocyte colony-stimulating factor in preventing febrile neutropenia. Support Care Cancer. 2025; 33:533. doi: 10.1007/s00520-025-09614-3
- Martynchyk A, Hawkes EA. SOHO state of the art updates and next questions | Does limited stage diffuse large B-cell lymphoma matter? Clin Lymphoma Myeloma Leuk. 2025:S2152–2650(25)00183–1.